Agios Pharmaceuticals Inc. (AGIO) Drops 5.28% on October 12

Equities Staff  |

Agios Pharmaceuticals Inc. (AGIO) was one of the Russell 2000's biggest losers for Wednesday October 12 as the stock slid 5.28% to $50.45, a loss of $-2.81 per share. Starting at an opening price of $53.16 a share, the stock traded between $50.25 and $54.09 over the course of the trading day. Volume was 577,764 shares over 6,743 trades, against an average daily volume of 755,910 shares and a total float of 38.05 million.

The losses send Agios Pharmaceuticals Inc. down to a market cap of $1.92 billion. In the last year, Agios Pharmaceuticals Inc. has traded between $81.77 and $33.50, and its 50-day SMA is currently $45.27 and 200-day SMA is $45.96.

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios Pharmaceuticals Inc. is based out of Cambridge, MA and has some 208 employees. Its CEO is David P. Schenkein.

For a complete fundamental analysis analysis of Agios Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for AGIO. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: